{"id":"NCT01543087","sponsor":"Pfizer","briefTitle":"Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose","officialTitle":"A PHASE 3 STUDY TO ASSESS THE PERSISTENCE OF HSBA RESPONSE UP TO 48 MONTHS AFTER COMPLETION OF A PRIMARY SERIES OF BIVALENT RLP2086, AND THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF BIVALENT RLP2086","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09-07","primaryCompletion":"2018-01-05","completion":"2018-01-05","firstPosted":"2012-03-02","resultsPosted":"2020-03-27","lastUpdate":"2020-03-27"},"enrollment":698,"design":{"allocation":null,"model":null,"masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Meningococcal Infection"],"interventions":[{"type":"PROCEDURE","name":"blood sampling","otherNames":[]},{"type":"DRUG","name":"bivalent rLP2086","otherNames":[]}],"arms":[{"label":"One group of subjects","type":"OTHER"}],"summary":"This study is to assess the longevity of immune response in adolescents for approximately 48 months after receipt of a primary series of bivalent rLP2086 vaccination, which is then followed by a booster dose and an assessment of immune response for 12 or 26 months post booster vaccination.","primaryOutcome":{"measure":"Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 6 (Visit 1) After Primary Vaccinations","timeFrame":"Month 6 (Visit 1 of study B1971033)","effectByArm":[{"arm":"Group 1:MCV4+Tdap+Saline (0-, 2-, and 6-Month Schedule)","deltaMin":14.3,"sd":null},{"arm":"Group 3a: rLP2086 (0-, 2-, and 6-Month Schedule)","deltaMin":86.5,"sd":null},{"arm":"Group 3c: rLP2086 (0-, 2-, and 6-Month Schedule))","deltaMin":83.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":56,"countries":["United States","Czechia","Denmark","Finland","Germany","Sweden"]},"refs":{"pmids":["30770221"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1971033&StudyName=Duration%20of%20Immunity%20Study"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":["Injection site pain (tenderness at injection site)","Fatigue","Headache","Chills","Myalgia"]}}